Most recently Dr Johnson was senior vice president of R&D at Nektar Therapeutics. Prior to Nektar, Dr Johnson was chief development officer for Control Delivery Systems.
Dr Johnston earned his bachelor’s and doctorate degrees in chemistry from St Andrews University (Scotland) and completed postdoctoral training at the Max Planck Institute for Medicinal Research (Heidelberg, Germany).
Dr Cannon said: “David is the most qualified person to take the company to the next level and create significant value. His successful experience in the inhaled drug delivery market and broader knowledge of drug development will be invaluable as we launch our initial therapeutic AeroCell-based products.”